Pharmaceutical company target list
Life-science teams that can benefit from clearer treatment-decision journeys.
Medinion can support patient education, specialist navigation, second-opinion readiness, and evidence-aware content across complex therapeutic areas. This page is a target-list research aid, not a claim of current partnership.
Searchable target table
Focus on therapeutic areas where patients face complex, high-stakes choices.
Pharmaceutical and diagnostics teams may care about education pathways, adherence support, patient access, clinical-trial awareness, biomarker testing, and specialist referral readiness.
Cardiometabolic and cardiovascular
-
Novo Nordisk
DK · Global
Cardiometabolic education and treatment-decision support are strong fit areas.
-
Pfizer
US · Global
Broad specialty reach makes education and access partnerships relevant.
-
Bayer
DE · Global
Cardiovascular and oncology education pathways are relevant.
-
Boehringer Ingelheim
DE · Global
Chronic disease education and specialist navigation fit the model.
Diagnostics, genomics, and testing
-
Foundation Medicine
US · Global
Biomarker education and oncology second opinions are highly aligned.
-
Guardant Health
US · Global
Testing education and treatment navigation are strong fit areas.
-
Exact Sciences
US · North America
Cancer screening and diagnostic uncertainty create education opportunities.
-
Tempus
US · North America
Precision medicine and oncology navigation align with Medinion content and review paths.
-
Illumina
US · Global
Genomic literacy and biomarker testing education are relevant.
-
Labcorp
US · North America
Lab results and specialty testing can feed second-opinion readiness.
-
Quest Diagnostics
US · North America
Testing access and report interpretation are strong patient education needs.
Neurology, immunology, and inflammation
-
Eli Lilly
US · Global
Multiple high-stakes therapy areas align with decision support and education.
-
AbbVie
US · Global
Immunology and oncology patient journeys can benefit from clearer education pathways.
-
Amgen
US · Global
Broad specialty portfolio with strong education and access needs.
-
Biogen
US · Global
Neurology diagnosis and treatment questions often need specialist review.
-
Johnson & Johnson Innovative Medicine
US · Global
Complex specialty portfolios fit Medinion education and navigation use cases.
-
UCB
BE · Global
Strong fit for complex chronic disease education and specialist navigation.
Oncology and hematology
-
AstraZeneca
GB · Global
Good fit for oncology education, biomarker testing, and patient navigation.
-
Bristol Myers Squibb
US · Global
Complex oncology and hematology decisions match second-opinion education needs.
-
Merck
US · Global
Cancer treatment education and clinical-trial awareness are strong fit areas.
-
Novartis
CH · Global
Broad specialty portfolio supports patient education and access pathways.
-
Roche and Genentech
CH · Global
Oncology education, biomarker testing, and treatment-decision support align well with Medinion.
-
BeiGene
CN · Global
Strong oncology focus makes it relevant for patient education and specialist navigation.
-
Daiichi Sankyo
JP · Global
Oncology portfolio fit for cancer treatment-decision support.
-
Gilead Sciences
US · Global
Oncology and specialty medicine education can benefit from structured review journeys.
Rare disease and specialty medicine
-
Alexion
US · Global
Rare disease diagnosis and treatment decisions are strong Medinion use cases.
-
Sanofi
FR · Global
Rare disease patients often need diagnostic clarity and specialist access.
-
Takeda
JP · Global
Good fit for complex specialty education and patient support pathways.
-
Vertex Pharmaceuticals
US · Global
Specialist navigation and education matter in complex rare disease care.
-
Alnylam Pharmaceuticals
US · Global
Complex therapy decisions and specialist routing are relevant to Medinion.
-
BioMarin
US · Global
Rare genetic disease treatment journeys need high-quality education and specialty review.